Analytical Data
-
Gene name
TNIP1
- Application
-
Alternative Names
TNIP1；KIAA0113；TNFAIP3-interacting Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15025
-
Expression Region
94-530aa
-
AA Sequence
MGSSHHHHHHSSGLVPRGSHMSNVTASPTAPACPSDKPAPVQKPPSSGTS SEFEVVTPEEQNSPESSSHANAMALGPLPREDGNLMLHLQRLETTLSVCA EEPDHGQLFTHLGRMALEFNRLASKVHKNEQRTSILQTLCEQLRKENEAL KAKLDKGLEQRDQAAERLREENLELKKLLMSNGNKEGASGRPGSPKMEGT GKKAVAGQQQASVTAGKVPEVVALGAAEKKVKMLEQQRSELLEVNKQWDQ HFRSMKQQYEQKITELRQKLADLQKQVTDLEAEREQKQRDFDRKLLLAKS KIEMEETDKEQLTAEAKELRQKVKYLQDQLSPLTRQREYQEKEIQRLNKA LEEALSIQTPPSSPPTAFGSPEGAGALLRKQELVTQNELLKQQVKIFEED FQRERSDRERMNEEKEELKKQVEKLQAQVTLSNAQLKAFKDEEKAREALR QQKRKAKA
-
Molecular Weight
52 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNIP1, or TNF receptor-associated peptide 1, is a critical protein involved in various cellular processes, including inflammation and immune response regulation. It acts as a negative regulator of the NF-κB signaling pathway, which is pivotal in mediating the effects of pro-inflammatory cytokines. Dysregulation of TNIP1 has been linked to several diseases, including autoimmune disorders, cancer, and chronic inflammatory conditions, highlighting its potential as a therapeutic target. Research into recombinant TNIP1 proteins has gained momentum as scientists seek to unravel its functional mechanisms and therapeutic implications. By producing and studying recombinant TNIP1, researchers aim to elucidate the protein's structural characteristics, binding interactions, and regulatory functions. Understanding these aspects can pave the way for the development of novel interventions to modulate TNIP1 activity, potentially leading to breakthroughs in treating diseases characterized by excessive inflammation or immune response dysfunction. As a result, the exploration of recombinant TNIP1 not only enhances our fundamental understanding of immune regulation but also holds promise for innovative therapeutic strategies targeting various pathologies related to TNIP1 dysregulation.
